CALC

SEC source: 0001415889-25-020164 · form4-07232025_030740.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 49,323

SEC source: 0001415889-25-020052 · form4-07212025_060739.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Scheibler-Leheny Family Living Trust

Disclosed balance after: 3,500

SEC source: 0001415889-25-020111 · form4-07222025_040709.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 47,823

F1 · price: The weighted average purchase price for the transaction reported was $3.3707, and the range of prices were between $3.33 and $3.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-019998 · form4-07182025_060737.xml · nonDerivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 422,029

SEC source: 0001415889-25-019997 · form4-07182025_060757.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 46,323

SEC source: 0001415889-25-019816 · form4-07162025_010710.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Scheibler-Leheny Family Living Trust

Disclosed balance after: 2,500

SEC source: 0001415889-25-019822 · form4-07162025_040730.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 44,323

F1 · price: The weighted average purchase price for the transaction reported was $2.4323, and the range of prices were between $2.30 and $2.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-019655 · form4-07112025_120755.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 37,823

SEC source: 0001415889-25-019190 · form4-07032025_010721.xml · nonDerivative · entry 1

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,000

SEC source: 0001415889-25-018309 · form4-06262025_100618.xml · nonDerivative · entry 1

Bardin Stephen · CIK 0001942596 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 3,000

F1 · price: The weighted average purchase price for the transaction reported was $1.5025, and the range of prices were between $1.45 and $1.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

F2 · balance_after: Includes 1,000 shares held by The Bardin Family Trust dated June 4, 2024 (the "Trust") which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.

F3 · ownership.nature: By The Bardin Family Trust dated June 4, 2024.

SEC source: 0001415889-25-018438 · form4-06272025_110619.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 32,823

F1 · price: The weighted average purchase price for the transaction reported was $1.4406, and the range of prices were between $1.43 and $1.4499. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-018310 · form4-06262025_100630.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,300

Underlying: Common Stock · 83,300 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018306 · form4-06262025_100621.xml · derivative · entry 1

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,125

Underlying: Common Stock · 47,125 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018305 · form4-06262025_100619.xml · derivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,625

Underlying: Common Stock · 77,625 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018297 · form4-06262025_100629.xml · derivative · entry 4

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-06-23

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.

SEC source: 0001415889-25-018297 · form4-06262025_100629.xml · derivative · entry 3

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,687

Underlying: Common Stock · 19,687 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

SEC source: 0001415889-25-018297 · form4-06262025_100629.xml · derivative · entry 2

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,562

Underlying: Common Stock · 6,562 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018297 · form4-06262025_100629.xml · derivative · entry 1

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

SEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 4

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-06-23

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.

SEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 3

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,562

Underlying: Common Stock · 36,562 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

SEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 2

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,031

Underlying: Common Stock · 12,031 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018298 · form4-06262025_100600.xml · derivative · entry 1

WILSON ROBERT N · CIK 0001189022 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

SEC source: 0001415889-25-018309 · form4-06262025_100618.xml · derivative · entry 3

Bardin Stephen · CIK 0001942596 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2035-04-22

F5 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F6 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018307 · form4-06262025_100613.xml · derivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,750

Underlying: Common Stock · 72,750 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018308 · form4-06262025_100610.xml · derivative · entry 1

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,125

Underlying: Common Stock · 47,125 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 4

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-06-23

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 2

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

SEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 4

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-06-23

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.

SEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 3

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

SEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 2

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,166

Underlying: Common Stock · 4,166 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018303 · form4-06262025_100646.xml · derivative · entry 1

Glicklich Alan · CIK 0001823197 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

SEC source: 0001415889-25-018300 · form4-06262025_100625.xml · derivative · entry 4

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-06-23

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.

SEC source: 0001415889-25-018300 · form4-06262025_100625.xml · derivative · entry 3

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 26,250 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

SEC source: 0001415889-25-018300 · form4-06262025_100625.xml · derivative · entry 2

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,594

Underlying: Common Stock · 8,594 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018300 · form4-06262025_100625.xml · derivative · entry 1

Shaw Allan · CIK 0001626850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

SEC source: 0001415889-25-017250 · form4-06132025_050601.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 28,323

SEC source: 0001415889-25-016218 · form4-06092025_080603.xml · nonDerivative · entry 2

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 23,323

F2 · price: The weighted average purchase price for the transaction reported was $1.755, and the range of prices were between $1.75 and $1.87. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-016218 · form4-06092025_080603.xml · nonDerivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By FMTC Custodian - Roth IRA FBO Eric W. Roberts

Disclosed balance after: 18,323

F1 · price: The weighted average purchase price for the transaction reported was $1.70, and the range of prices were between $1.6638 an $1.7274. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-015421 · form4-06032025_050601.xml · nonDerivative · entry 1

Bardin Stephen · CIK 0001942596 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,000

SEC source: 0001415889-25-011359 · form4-04252025_080420.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001415889-25-011361 · form4-04252025_080404.xml · derivative · entry 1

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001415889-25-011358 · form4-04252025_080419.xml · derivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 285,000

Underlying: Common Stock · 285,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001415889-25-011365 · form4-04252025_080459.xml · derivative · entry 1

Bardin Stephen · CIK 0001942596 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001415889-25-011362 · form4-04252025_080402.xml · derivative · entry 1

Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001415889-25-011360 · form4-04252025_080421.xml · derivative · entry 1

Roberts Eric W · CIK 0001576244 · Director · CHIEF BUSINESS OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2035-04-22

F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period.

SEC source: 0001968793-26-000002 · form4-04072026_090409.xml · derivative · entry 1

Hebbar Sudarshan · CIK 0001968793 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,173

Underlying: Common Stock · 91,173 shares

Expires 2036-04-04

F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

SEC source: 0001968792-26-000002 · form4-04072026_090405.xml · derivative · entry 1

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,124

Underlying: Common Stock · 65,124 shares

Expires 2036-04-04

F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.

SEC source: 0001484729-26-000002 · form4-04072026_090402.xml · derivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,482

Underlying: Common Stock · 148,482 shares

Expires 2036-04-04

F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision.